晚期BRAF突变结直肠癌的靶向治疗:系统综述与网状Meta分析
该系统综述与网状Meta分析纳入60项研究共4633例晚期BRAF突变结直肠癌患者,评估靶向治疗策略的疗效与安全性。一线治疗中双药化疗联合抗EGFR/BRAF的总生存最优,优于双药化疗联合抗VEGF(HR 0.49,95%CrI 0.36至0.66)。后线治疗中抗EGFR/BRAF方案(联合或不联合MEK抑制剂)疗效与耐受性最佳。
要点
- 一线双药化疗联合抗EGFR/BRAF较双药化疗联合抗VEGF显著改善总生存(HR 0.49,95%CrI 0.36至0.66)。
- 一线双药化疗联合抗EGFR/BRAF的SUCRA总生存为0.94、无进展生存为0.93,排名最高。
- 后线抗EGFR/BRAF方案(联合或不联合MEK抑制剂)在各研究终点排名最高。
核心结论
- 对于晚期BRAF突变结直肠癌的初始治疗,双药化疗联合抗EGFR/BRAF方案提供最佳生存获益。
- 对于既往接受过治疗的患者,抗EGFR/BRAF方案(联合或不联合MEK抑制剂)是最有效且可耐受的选择。
研究设计与样本
- 系统综述与网状Meta分析,检索PubMed、Embase、Cochrane Library和ClinicalTrials.gov自建库至2025年5月31日及国际会议论文集。
- 纳入临床试验及多中心真实世界研究,共60项研究、4633例晚期BRAF突变结直肠癌患者。
主要发现
- 汇总估计提示患者可从抗EGFR/BRAF方案中获益。
- 一线治疗中双药化疗联合抗EGFR/BRAF较双药化疗联合抗VEGF显著改善总生存(HR 0.49,95%CrI 0.36至0.66)。
- 一线治疗中双药化疗联合抗EGFR/BRAF较三药化疗联合抗VEGF显著改善总生存(HR 0.51,95%CrI 0.33至0.80)。
- 一线治疗中双药化疗联合抗EGFR/BRAF较抗EGFR/BRAF显著改善总生存(HR 0.70,95%CrI 0.51至0.96)。
- 后线治疗中抗EGFR/BRAF联合或不联合额外抑制剂(抗MEK或抗PI3K)较其他替代策略疗效更优,基于排名概率和SUCRA在各研究终点排名最高。
关键数值与推荐
- 一线双药化疗联合抗EGFR/BRAF的总生存SUCRA为0.94,单药化疗联合抗EGFR/BRAF为0.90。
- 一线双药化疗联合抗EGFR/BRAF的无进展生存SUCRA为0.93,单药化疗联合抗EGFR/BRAF为0.92。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the individual and comparative efficacy and safety of targeted therapy based strategies in advanced BRAF-mutated colorectal cancer. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: PubMed, Embase, Cochrane Library, and ClinicalTrials.gov from inception to 31 May 2025, and international conference proceedings. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Clinical trials and multicentre, real world studies investigating the efficacy and safety of targeted therapies for advanced BRAF-mutated colorectal cancer with at least one of the clinical outcomes of interest. DATA SYNTHESIS: The primary endpoint was overall survival in the first line and second or later line settings. Secondary endpoints included progression-free survival, objective response rate, disease control rate, and grade ≥3 adverse events. Single arm meta-analysis, pairwise meta-analysis, and network meta-analysis were performed to pool hazard ratios with 95% credible intervals (CrIs) for overall survival and progression-free survival, and odds ratios with 95% CrIs for objective response rate, disease control rate, and adverse events. The rankogram and surface under the cumulative ranking curve (SUCRA) evaluated the relative superiority of regimens in the network meta-analysis. RESULTS: 60 studies involving 4633 patients with advanced BRAF-mutated colorectal cancer were included. Pooled estimates indicated that patients could benefit from an anti-EGFR (epidermal growth factor receptor)/BRAF based regimen. Doublet chemotherapy (DCT)-anti-EGFR/BRAF was associated with the best overall survival, providing significant benefits compared with DCT-anti-VEGF (vascular endothelial growth factor) (hazard ratio 0.49, 95% CrI 0.36 to 0.66), triplet chemotherapy-anti-VEGF (0.51, 0.33 to 0.80), and anti-EGFR/BRAF (0.70, 0.51 to 0.96) regimens in the first line setting. Chemotherapy-anti-EGFR/BRAF showed significant superiority in overall survival (SUCRA=0.94 for DCT-anti-EGFR/BRAF, 0.90 for single agent chemotherapy (SCT)-anti-EGFR/BRAF) and progression-free survival (0.93 for DCT-anti-EGFR/BRAF and 0.92 for SCT-anti-EGFR/BRAF) among all first line targeted therapy strategies. In the second or later line setting, anti-EGFR/BRAF with or without an additional inhibitor (anti-MEK (mitogen-activated protein kinase kinase) or anti-PI3K (phosphoinositide 3-kinase)), exhibited better efficacy compared with other alternative strategies, ranking highest across study endpoints based on rank probability and SUCRA. CONCLUSIONS: For initial treatment of advanced BRAF-mutated colorectal cancer, combining doublet chemotherapy with anti-EGFR/BRAF therapy offers the best survival benefit. For patients who have had previous treatment, anti-EGFR/BRAF regimens (with or without a MEK inhibitor) are the most effective and tolerable options. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD420250653959.
引用
- Qin BD, Jiao XD, Wang Z, et al. Targeted therapy in advanced BRAF-mutated colorectal cancer: systematic review and network meta-analysis. BMJ. 2025. PMID: 41355781. doi:10.1136/bmj-2025-086026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。